Company profile: Replimune
1.1 - Company Overview
Company description
- Provider of next-generation oncolytic immunotherapies for cancer, developing proprietary products that enhance direct anti-tumor effects of selective virus replication and boost immune responses to tumor antigens. Products include RP1 (HSV-1 strain with immune-activating transgenes), RP2 (anti-CTLA-4 antibody targeting immunologically silent tumors to enhance tumor killing and immune response), and RP3 (CD40L and 4-1BBL ligands).
Products and services
- RP3: Features addition of immune costimulatory pathway activating ligands CD40L and 4-1BBL to stimulate a powerful immune response and potentially reduce side effects, delivered as a custom-engineered product
- RP2: Incorporates an anti-CTLA-4 antibody targeting more immunologically silent tumors, aiming to enhance tumor killing and immune response in a next-generation, antibody-augmented design
- RP1: An oncolytic immunotherapy for more immune responsive tumor types, utilizing a proprietary HSV-1 strain and immune activating transgenes within a genetically engineered construct.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Replimune
Adaptate Biotherapeutics
HQ: Canada
Website
- Description: Provider of antibodies designed to modulate gamma delta T cells in situ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptate Biotherapeutics company profile →
Be Bio
HQ: United States
Website
- Description: Provider of engineered B cell medicines for serious genetic diseases, including BE-101 to produce active and sustained Factor IX for Hemophilia B. Offers BCMs engineered to produce highly active and sustained antitumor biologics for cancer, and BCMs designed to produce therapeutic proteins for genetic and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Be Bio company profile →
MedImmune
HQ: United States
Website
- Description: Provider of biologics research and development as the global biologics research and development arm of AstraZeneca, developing medicines for unmet medical needs worldwide and pioneering innovative research and exploring novel pathways across key therapeutic areas including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; and neuroscience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedImmune company profile →
Abpro
HQ: United States
Website
- Description: Provider of next-generation antibody therapeutics, diagnostics, and research solutions using DiversImmune and MultiMab platforms to discover and engineer high-affinity, high-specificity bi- and multi-specific antibodies against difficult targets, including the TetraBi tetravalent bispecific format for T-cell engagement with bivalent tumor antigen binding, Fc modification, and flexible configurations to enhance safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abpro company profile →
Harpoon Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapy developing novel T cell-engaging biologic therapies that harness the body’s immune system to direct patients’ T cells to kill target cells in cancer and other diseases, including the TriTAC Technology antibody-based drug discovery platform designed to enhance immune targeting and killing of cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harpoon Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Replimune
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Replimune
2.2 - Growth funds investing in similar companies to Replimune
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Replimune
4.2 - Public trading comparable groups for Replimune
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →